ArticleJournal of oral microbiology2026
Cell-type-specific actions of carnosic acid against
Article in Journal of oral microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: The periodontal pathogen Objective: To investigate the oncogenic effects of Pg and its lipopolysaccharide (LPS) on liver cancer cells and evaluate the anti‑cancer potential of carnosic acid (CA). Design: HepG2, HuH7 and pancreatic cancer cells were treated with Pg, Pg‑LPS or CA. Proliferation was assessed by viability assay. Key phosphorylated signaling molecules and their total proteins (TLR4, ERK, Akt, NF‑κB, Nrf2) were examined by western blot and immunofluorescence. Results: Pg promoted proliferation in HepG2 and pancreatic cancer cells in an MOI‑dependent manner and upregulated TLR4, p‑ERK, p‑Akt and p‑NF‑κB. Pg‑LPS enhanced proliferation, but CA did not inhibit this effect. In HuH7 cells, CA inhibited proliferation, associated with Nrf2 activation; in HepG2 cells, CA showed no inhibition or Nrf2 activation. Conclusions: Pg promotes oncogenic processes. CA modulates proliferation in a cell‑type‑ and concentration‑dependent manner, likely through Nrf2 activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.